Table 2.
Antibody responses to treponemal antigens rp17 and TmpA by site
| Site | Age (years) | Number sampled | Anti–rp17+ | Anti–TmpA+ | Anti–rp17 + and anti–TmpA+ | |||
|---|---|---|---|---|---|---|---|---|
| n | % (95% CI) | n | % (95% CI) | n | % (95% CI) | |||
| Nayapara Registered Camp | 1–4 | 147 | 5 | 3.4 (1.1–7.8) | 1 | 0.68 (0–3.7) | 0 | 0 (0–2.5) |
| 5–6 | 126 | 3 | 2.4 (0–5.0) | 1 | 0.37 (0–2.3) | 0 | 0 (0–17) | |
| All | 273 | 8 | 2.9 (0.9–4.9) | 2 | 0.73 (0–1.7) | 0 | 0 (0–1.1) | |
| Makeshift Settlements | 1–4 | 246 | 13 | 5.3 (2.8–8.9) | 2 | 0.81 (0.1–2.9) | 1 | 0.4 (0–2.2) |
| 5–14 | 411 | 9 | 2.2 (1.0–4.1) | 4 | 0.97 (0.3–2.5) | 0 | 0 (0–0.9) | |
| All | 657 | 22 | 3.3 (2.1–5.0) | 6 | 0.91 (0.3–2.0) | 1 | 0.15 (0–0.8) | |
CI = confidence interval; n = number positive; rp17 = recombinant protein17; TmpA = treponemal membrane protein A. When antibody prevalence was 0, binomial exact calculation using one-sided 97.5% CI was used.